Live cell and high content imaging approaches identify apoptosis inducers in cell models of triple negative breast cancer
Improved Five-Year Survival Rates for Breast Cancer with Targeted Therapies
In recent years, significant progress has been made in improving the five-year survival rates for breast cancer, thanks to the successful identification and implementation of new and enhanced treatment options. However, one subtype, known as triple negative breast cancer (TNBC), has proven to be a challenging therapeutic target, resulting in a notably poorer prognosis compared to other breast cancer types.
To tackle this issue, researchers have employed innovative methods to identify small molecules that specifically target TNBC. They utilised two cutting-edge imaging platforms to conduct multiplexed assays focused on cell apoptosis and viability. The IncuCyte ZOOM system enables real-time kinetic monitoring of cell health, tracking both viability and cell death. On the other hand, the ImageXpress Micro Confocal platform serves as a high-content confocal imaging system, well-suited for efficient high-throughput screening applications.
By employing multiplexed assay formats across these advanced imaging platforms, researchers can confidently identify promising therapeutic strategies to effectively target triple negative breast cancer cells. This ground-breaking approach holds great potential to further enhance the treatment and survival outcomes for TNBC patients.